U.S. markets open in 40 minutes
  • S&P Futures

    4,519.75
    -8.25 (-0.18%)
     
  • Dow Futures

    35,421.00
    -56.00 (-0.16%)
     
  • Nasdaq Futures

    15,342.50
    -35.00 (-0.23%)
     
  • Russell 2000 Futures

    2,285.30
    -2.20 (-0.10%)
     
  • Crude Oil

    83.04
    -0.38 (-0.46%)
     
  • Gold

    1,784.90
    0.00 (0.00%)
     
  • Silver

    24.35
    -0.09 (-0.39%)
     
  • EUR/USD

    1.1650
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.6660
    +0.0300 (+1.83%)
     
  • Vix

    15.91
    +0.21 (+1.34%)
     
  • GBP/USD

    1.3812
    -0.0014 (-0.10%)
     
  • USD/JPY

    113.9800
    -0.3490 (-0.31%)
     
  • BTC-USD

    65,022.57
    +674.87 (+1.05%)
     
  • CMC Crypto 200

    1,537.35
    +56.54 (+3.82%)
     
  • FTSE 100

    7,191.00
    -32.10 (-0.44%)
     
  • Nikkei 225

    28,708.58
    -546.97 (-1.87%)
     

Why Crispr's Gene-Editing Dive Helped Reinvigorate Its Chief Rival, Allogene

·3 min read
Why Crispr's Gene-Editing Dive Helped Reinvigorate Its Chief Rival, Allogene
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Analysts were split Wednesday as they compared Crispr's gene-edited cancer drug to Allogene's — but CRSP stock tumbled as ALLO stock popped.